Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. PET/MRI for Preoperative Planning in Patients with Soft Tissue Sarcoma: A Technical Report of Two Patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Massive fetomaternal hemorrhage caused by an intraplacental choriocarcinoma: a case report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  1. Ciclosporin

    Publikation: Bog/antologi/afhandling/rapportRapportRådgivning

  2. Factors associated with citation of original articles in 5 high-impact-factor dermatology journals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Patients with a familial predisposition to hidradenitis suppurativa have a distinct clinical phenotype

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Online Patient Recruitment in Clinical Trials: Systematic Review and Meta-Analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer
Chronic spontaneous urticaria is an itching skin disease characterised by wheals, angioedema, or both present for more than six weeks. Omalizumab is a humanized anti-IgE monoclonal antibody recently approved for treatment of chronic urticaria. Several randomised controlled trials have investigated the safety, tolerability, and efficacy of omalizumab for chronic urticaria. The safety of omalizumab in pregnancy is not known. We describe a female patient with chronic spontaneous urticaria who was treated with omalizumab continuously through two consecutive pregnancies with convincing results and no apparent toxicity.
OriginalsprogEngelsk
TidsskriftCase reports in medicine
Vol/bind2015
Sider (fra-til)368053
ISSN1687-9627
DOI
StatusUdgivet - 2015

ID: 46234646